Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
FIDES-01 trial: what clinicians have said so far
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
- NCT03230318 ↗
- Completed
- Basilea Pharmaceutica
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on FIDES-01 (derazantinib in FGFR2 fusion-, mutation- or amplification-positive advanced intrahepatic cholangiocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIDES-01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- A Pivotal Study of Derazantinib in Patients With Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Gene Fusions or FGFR2 Gene Mutations or Amplifications
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Intrahepatic Cholangiocarcinoma; Combined Hepatocellular and Cholangiocarcinoma
- Interventions
- derazantinib
- Arms
- derazantinib · Experimental
- Enrollment
- 148
- Primary outcomes
- Substudy 1: Objective Response Rate (ORR)
- Substudy 2: Progression Free Survival at 3 Months (PFS 3)
- Sponsor
- Basilea Pharmaceutica
- Start
- Sep 28, 2017
- Primary completion
- Oct 25, 2022
- Results posted
- Yes
- Registry record
- NCT03230318 · updated Dec 19, 2023
Publications
linked from the registry- Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, Masi G, Rimassa L, Personeni N, Braiteh F, Zagonel V, Papadopoulos KP, Hall T, Wang Y, Schwartz B, Kazakin J, Bhoori S, de Braud F, Shaib WL. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13. PubMed 30420614